维奈克拉联合阿扎胞苷治疗复发难治性急性髓系白血病的临床效果

Clinical effect of Vinecra combined with azacytidine in the treatment of relapsed refractory acute myeloid leukemia

目的:分析对复发难治性急性髓系白血病患者行维奈克拉联合阿扎胞苷治疗的效果。方法:选取2020年1月—2022年12月金乡县人民医院收治的60例复发难治性急性髓系白血病患者,根据随机数字表法随机分为对照组(30例,接受阿扎胞苷治疗)和观察组(30例,接受维奈克拉联合阿扎胞苷治疗),比较两组的治疗效果。结果:观察组总缓解率高于对照组,差异有统计学意义(P<0.05)。观察组血小板计数、白细胞计数高于对照组,骨髓原始细胞比例低于对照组,差异有统计学意义(P<0.05)。观察组CD3^(+)、CD4^(+)、CD8^(+)水平低于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:复发难治性急性髓系白血病患者接受维奈克拉联合阿扎胞苷治疗效果确切,可显著改善患者血液指标,提高自身免疫功能,同时不增加不良反应,有较高应用价值。

Objective To analyze the effect of venekra combined with azacitidine in patients with relapsed refractory acute myeloid leukemia.Methods A total of 60 patients with relapsed and refractory acute myeloid leukemia treated in Jinxiang County People's Hospital from January 2020 to December 2022 were randomly divided into control group(30 cases receiving azacitidine)and observation group(30 cases receiving Vinecra combined with azacitidine)according to random number table method.The therapeutic effect of the two groups was compared.Results The total remission rate in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).The platelet count and white blood cell count in the observation group were higher than those in the control group,and the proportion of bone marrow original cells was lower than that in the control group,with statistical significance(P<0.05).The levels of CD3^(+),CD4^(+) and CD8^(+) in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusions Patients with relapsed refractory acute myeloid leukemia receive Vinecra combined with azacitidine,which can significantly improve blood indexes and autoimmune function without increasing adverse reactions,and has high application value.